Navigation Links
Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
Date:1/23/2013

novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines or other receptors thereby reducing the likelihood of "off target" side effects.  NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.

NBI-98854 may also be useful in other disorders such as Huntington's chorea, schizophrenia, Tourette's syndrome, and tardive dystonia.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
2. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
4. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
5. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
6. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
10. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
11. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Today we bring you a special edition of #MedicareMonday on ... you about some of our Medicare resources and continue highlighting the success of the ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
(Date:7/30/2015)... 2015 Eisai Inc. announced today that regulatory ... States , European Union and Japan ... for eribulin, for the treatment of patients with inoperable ... for advanced or metastatic disease. These ... global Phase 3 clinical trial (Study 309), which met ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... HOUSTON, May 2, 2011 Otto Kaiser Memorial Hospital ... in favor of ChartAccess® Comprehensive EHR from Prognosis Health ... 25-bed hospital comply with the federal government,s meaningful use ... health information organization (RHIO). "We,re known ...
... N.Y., May 2, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... America Merrill Lynch 2011 Health Care Conference on Tuesday, May ... Time).  The session may be accessed through the Company,s web ... archived version of the presentation will be available after the ...
Cached Medicine Technology:Otto Kaiser Memorial Hospital Turns to Prognosis ChartAccess® Comprehensive EHR to Meet Organizational Aspirations 2Otto Kaiser Memorial Hospital Turns to Prognosis ChartAccess® Comprehensive EHR to Meet Organizational Aspirations 3
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money and ... containment — or even destruction — of products, an FDA insider shows manufacturers ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby ... post that encourages the understanding and treatment of ankle sprains. A common sports ... remedies. This can be dangerous if the condition augments and causes more disruption. ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark ... for LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The ... post-acute care providers understand the benefits of using medication management technologies . ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... The following is a,statement by Bonnie J. Campbell, ... jury unanimously concluded that former manufacturers,of lead pigment used ... the,harm claimed by this plaintiff. The jury unanimously found ... paint., "Under Wisconsin law, property owners are legally ...
... Rhythm Congress 2007 ... Live EP Cases in Birmingham, UK, CARLSBAD, ... company, announced today its successful first,public broadcast of a procedure ... by Dr. Lucas Boersma of the St. Antonius,Hospital in Nieuwegein, ...
... five treated babies doesn,t have excess stomach acid, study ... may be overprescribing anti-reflux medications to infants, new research ... in five babies given anti-reflux medications, which work by ... levels. That means four out of five infants included ...
... of choice to manage abnormal heart rhythms, a new ... School of Medicine suggests that women with ICDs fare ... retrospective analysis to be presented at the AHA Scientific ... p.m.), lead researcher Andrea Russo, M.D., Clinical Associate Professor ...
... Guatemala, Nov. 5 World-renowned heart,surgeon Dr. Rafael Espada ... President of Guatemala. President-elect Alvaro Colom, with Dr.,Espada as ... than 52.8 percent of the country,s votes. The two ... Guatemala, Dr. Espada has practiced for more than 30 ...
... Nov. 5 Lincoln Financial,Advisors, part of ... announced today that it has entered into ... to provide its members access to,services provided ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050830/LFLOGO ) ...
Cached Medicine News:Health News:First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time 2Health News:First in the World Live Case Using New Technology Demonstrates Shorter Procedure Time 3Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 2Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 3Health News:Do women fare worse with some heart devices? 2Health News:Houston Heart Surgeon Elected Vice President of Guatemala 2Health News:Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members 2Health News:Lincoln Financial Advisors to Provide Exclusive Services to American Osteopathic Association Members 3
... OraQuick is an FDA ... venipuncture whole blood test used ... of HIV-1 infection. This CLIA ... presence of antibodies to HIV-1, ...
... Mononucleosis test is designed to detect ... plasma or whole blood. The QuickVue+ ... of bovine erythrocytes which give a ... extracts prepared from sheep and horse ...
... available point-of-care diagnostic test that can reliably ... A and B. The test uses a ... that assists viral replication by promoting the ... The ZstatFlu substrate is labeled with a ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
Medicine Products: